5-α-Reductase Inhibition and Prostate Cancer Prevention

Otis W. Brawley, Leslie G. Ford, Jeffrey A. Perlman, Barnett S. Kramer, Ian Thompson

Research output: Contribution to journalArticle

Abstract

Studies of prostate biology support the concept that dihydrotestosterone is the principal androgen responsible for normal and hyperplastic growth of the prostate gland. Cancer is a process of malignant transformation evolving over time, involving cellular growth and division. Therefore, an altered endocrine state, such as suppression of dihydrotestosterone activity, may have an impact on prostate cells inhibiting carcinogenic transformation. In vitro and in vivo preclinical observations support this hypothesis. A placebo-controlled randomized trial using finasteride, an inhibitor of the enzyme that converts testosterone to dihydrotestosterone, is planned. The endpoint of this trial will be reduction of prostate cancer incidence.

Original languageEnglish (US)
Pages (from-to)177-182
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Volume3
Issue number2
StatePublished - Mar 1 1994
Externally publishedYes

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Fingerprint Dive into the research topics of '5-α-Reductase Inhibition and Prostate Cancer Prevention'. Together they form a unique fingerprint.

  • Cite this

    Brawley, O. W., Ford, L. G., Perlman, J. A., Kramer, B. S., & Thompson, I. (1994). 5-α-Reductase Inhibition and Prostate Cancer Prevention. Cancer Epidemiology Biomarkers and Prevention, 3(2), 177-182.